Open AccessTowards a cancer mission in Horizon Europe: recommendations
Author(s) -
Berns Anton,
Ringborg Ulrik,
Celis Julio E.,
Heitor Manuel,
Aaronson Neil K.,
AbouZeid Nancy,
Adami HansOlov,
Apostolidis Kathi,
Baumann Michael,
Bardelli Alberto,
Bernards René,
Brandberg Yvonne,
Caldas Carlos,
Calvo Fabien,
Dive Caroline,
Eggert Angelika,
Eggermont Alexander,
Espina Carolina,
Falkenburg Frederik,
Foucaud Jérôme,
Hanahan Douglas,
Helbig Ulrike,
Jönsson Bengt,
Kalager Mette,
Karjalainen Sakari,
Kásler Miklós,
Kearns Pamela,
Kärre Klas,
Lacombe Denis,
Lorenzo Francesco,
Meunier Françoise,
Nettekoven Gerd,
Oberst Simon,
Nagy Péter,
Philip Thierry,
Price Richard,
Schüz Joachim,
Solary Eric,
Strang Peter,
Tabernero Josep,
Voest Emile
Publication year - 2020
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12763
Subject(s) - harmonization , translational research , european union , business , portfolio , health care , member states , sustainability , political science , risk analysis (engineering) , public relations , medicine , international trade , finance , biology , ecology , pathology , acoustics , law , physics
A comprehensive cancer approach covering the entire research–care–prevention continuum can achieve a 10‐year cancer‐specific survival for 75% of patients diagnosed in EU member states with well‐developed health care by 2030. To ensure access to a critical mass of patient biological and technological resources, infrastructures for translational research, clinical and prevention trials, and outcomes research are needed. Here, we provide recommendations for achieving key targets and prioritize research areas.